You now have access to all the content in the PAREXEL Access Hub. We look forward to engaging with you.
We will be in touch shortly.
Please complete our registration form to continue.
Before a trial has gone too far and too much money has already been spent, evidence-based prioritization helps to identify the right product for the right indication. This minimizes investment risks and avoids unnecessary competition.
Predicting the success of the entire drug discovery process using an evidence-based approach at the start of development can inform trial design, feasibility and commercial strategy.
This exercise prevents:
• Competition at the reimbursement stage
• Missed collaboration opportunities
• Investment risk
This exercise identifies:
• Potential market size
• Likely competitor developments
• Information already known about a particular compound’s safety
Pricing & Reimbursement
Regulatory & Payer Submissions